Business Recorder reported that a drug already approved for treating kidney cancer was successful at delaying the return of advanced ovarian cancer by an average of nearly six months, a clinical study said.

A quoted in the market news:

German researchers found that the GlaxoSmithKlein drug pazopanib (Votrient) extended the median time to disease worsening to 17.9 months compared with 12.3 months for patients given a placebo in a phase III clinical trial.
“Our findings show that we finally have a drug that can maintain control over ovarian cancer growth achieved through initial treatments,” said lead author Andreas du Bois, a professor of gynaecologic oncology at Kliniken Essen Mitte in Germany.

The drug

Click here for the full news report by Business Recorder

cancer oncology phase iii Company News